Clinic Director in Tokyo Receives Improvement Order Regarding Regenerative Medicine (Published February 20, 2026) | NNN

News Summary

The director of a clinic in Tokyo has received an improvement order from the Minister of Health, Labour and Welfare due to inappropriate advertising related to regenerative medicine. Specifically, the clinic was cited for advertising efficacy and indications for unapproved regenerative medicine products, misleading patients. This situation highlights the increasing strictness of advertising regulations in the regenerative medicine field and the importance of compliance for medical institutions.

M&A Medical Editorial Department’s Perspective

The improvement order issued to a Tokyo-based clinic, as reported by NNN, serves as another example underscoring the stringent advertising regulations in the regenerative medicine sector. Advertising efficacy and indications for unapproved regenerative medicine products as if they were approved is a violation of the Medical Advertising Guidelines. This not only misleads patients but also directly leads to a loss of the clinic’s credibility. Regenerative medicine is a relatively new field where information can easily become muddled. In such circumstances, if management neglects compliance, there is a significant risk of substantial impact on business operations through administrative actions. From an M&A perspective, during due diligence, the compliance status of advertising, particularly adherence to regulations in the regenerative medicine field, can represent a hidden risk for the target clinic. Thoroughly reviewing past advertising practices and any history of administrative guidance is essential for avoiding risks post-M&A.

Points Raised by This News

• The tightening of advertising regulations in the regenerative medicine field and the risks associated with advertising efficacy for unapproved products.
• A concrete example of how a clinic’s advertising representations can mislead patients and lead to administrative action.
• The importance of verifying advertising compliance during M&A due diligence.
• The necessity for management and successors to have information literacy and adhere to regulations, considering the specific characteristics of the regenerative medicine field.

Practical Questions Arising from This News

• What were the specific advertising expressions that led to this improvement order?
• Are there other clinics currently engaging in similar advertising practices?
• What aspects of advertising should be considered when contemplating an M&A in the regenerative medicine field?

If You Feel “Should I Consult?”

Medical institution directors who are concerned about whether their clinic’s advertising representations comply with the latest regulations regarding regenerative medicine products, or who have experienced similar guidance in the past, are encouraged to consult with specialists. When considering an M&A, the advertising compliance status of the target company is a crucial factor in evaluating future risks. Our expert team will conduct a detailed hearing of your clinic’s situation and propose appropriate advice and M&A strategies.

M&A Medical (CentralMedience Inc.) supports business succession for medical corporations, hospitals, and clinics with a complete success-fee basis, as an M&A support institution certified by the Small and Medium Enterprise Agency. Consultations are handled with strict confidentiality. Free consultation here